Cargando…
Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialize...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317875/ https://www.ncbi.nlm.nih.gov/pubmed/34337524 http://dx.doi.org/10.1016/j.euros.2021.04.004 |
_version_ | 1783730137748996096 |
---|---|
author | Bergroth, Robin Matikainen, Mika Rannikko, Antti |
author_facet | Bergroth, Robin Matikainen, Mika Rannikko, Antti |
author_sort | Bergroth, Robin |
collection | PubMed |
description | The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialized nurses, or general practitioners. Despite the increase in patient numbers, resources are not likely to increase in proportion. Furthermore, the ongoing COVID-19 pandemic has led to a paradigm shift in our thinking towards telehealth solutions, primarily to avoid or limit physical contact and to spare resources. Here we report our novel telehealth solution for PCa follow-up, called Mobile PSA. Currently, more than 4500 PCa patients have been using Mobile PSA follow-up in our center. Mobile PSA can increase follow-up accuracy, as all biochemical relapses will be detected in a timely manner, can significantly reduce delays in reporting prostate-specific antigen results to patients, and can significantly reduce costs. PATIENT SUMMARY: We assessed a new telehealth information system for prostate cancer follow-up that does not use an app. More than 4500 prostate cancer patients in our center have used this system, called Mobile PSA, for follow-up. The system significantly reduces delays in reporting prostate-specific antigen (PSA) test results to patients, increases the accuracy of detecting recurrence of elevated PSA, and reduces costs. |
format | Online Article Text |
id | pubmed-8317875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83178752021-07-29 Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up Bergroth, Robin Matikainen, Mika Rannikko, Antti Eur Urol Open Sci Brief Correspondence The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialized nurses, or general practitioners. Despite the increase in patient numbers, resources are not likely to increase in proportion. Furthermore, the ongoing COVID-19 pandemic has led to a paradigm shift in our thinking towards telehealth solutions, primarily to avoid or limit physical contact and to spare resources. Here we report our novel telehealth solution for PCa follow-up, called Mobile PSA. Currently, more than 4500 PCa patients have been using Mobile PSA follow-up in our center. Mobile PSA can increase follow-up accuracy, as all biochemical relapses will be detected in a timely manner, can significantly reduce delays in reporting prostate-specific antigen results to patients, and can significantly reduce costs. PATIENT SUMMARY: We assessed a new telehealth information system for prostate cancer follow-up that does not use an app. More than 4500 prostate cancer patients in our center have used this system, called Mobile PSA, for follow-up. The system significantly reduces delays in reporting prostate-specific antigen (PSA) test results to patients, increases the accuracy of detecting recurrence of elevated PSA, and reduces costs. Elsevier 2021-04-29 /pmc/articles/PMC8317875/ /pubmed/34337524 http://dx.doi.org/10.1016/j.euros.2021.04.004 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Correspondence Bergroth, Robin Matikainen, Mika Rannikko, Antti Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up |
title | Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up |
title_full | Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up |
title_fullStr | Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up |
title_full_unstemmed | Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up |
title_short | Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up |
title_sort | mobile psa: a novel telehealth tool for prostate cancer follow-up |
topic | Brief Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317875/ https://www.ncbi.nlm.nih.gov/pubmed/34337524 http://dx.doi.org/10.1016/j.euros.2021.04.004 |
work_keys_str_mv | AT bergrothrobin mobilepsaanoveltelehealthtoolforprostatecancerfollowup AT matikainenmika mobilepsaanoveltelehealthtoolforprostatecancerfollowup AT rannikkoantti mobilepsaanoveltelehealthtoolforprostatecancerfollowup |